XETR
FME
Market cap12bUSD
Sep 17, Last price
39.00EUR
1D
-2.57%
1Q
-4.18%
Jan 2017
-51.52%
Name
Fresenius Medical Care AG & Co KGaA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fresenius Medical Care AG & Co. KGaA, established in Bad Homburg, Germany, in 1996, operates as a global provider of dialysis care and associated services. The company boasts an extensive international footprint, managing 4,171 outpatient dialysis clinics across approximately 150 countries (as of February 23, 2022), with significant operations in Germany and North America. Its comprehensive service portfolio includes in-clinic dialysis treatments, supported by laboratory and diagnostic services, alongside robust home dialysis programs that provide essential materials, training, patient monitoring, and supply delivery. Fresenius Medical Care also contracts with hospitals in the United States to deliver dialysis care to hospitalized patients suffering from acute kidney failure or end-stage renal disease. Beyond core dialysis, the company offers specialized medical services in vascular, cardiovascular, endovascular, nephrology, and cardiology. A key player in medical technology, Fresenius Medical Care actively develops, manufactures, and distributes a broad spectrum of dialysis products. This range encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, hemodialysis concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. They also produce non-dialysis items like acute cardiopulmonary and apheresis products. The firm is additionally involved in the pharmaceutical sector, developing, acquiring, and licensing renal medications and supplies for direct distribution to patients' homes or dialysis clinics. Products are sold to dialysis clinics, hospitals, and specialized treatment centers through direct channels, local sales forces, and a network of independent distributors, dealers, and agents.
Related entities
Subsidiaries (69)
(ju) peulejeniuseumedikalkeeokolia
BIOCARE TECHNOLOGY COMPANY LIMITED
bris'ath fer si neiy s medi khxl khaer cakad
brisath fer si neiy s medi khxl khaer (prathesthiy) cakad
fei sen you si yi yao yong pin (shang hai) you xian gong si
FMC FINANCE II S.A R.L.
Fresenius Management Services, Inc.
FRESENIUS MEDICAL CARE (HOLDINGS) LIMITED
FRESENIUS MEDICAL CARE (IRELAND) LIMITED
Fresenius Medical Care (Jiangsu) Co., Ltd.
Fresenius Medical Care (Schweiz) AG
FRESENIUS MEDICAL CARE (UK) LIMITED
Fresenius Medical Care - CR, s.r.o.
Fresenius Medical Care - DS, s.r.o.
Fresenius Medical Care Argentina S.A.
Fresenius Medical Care Australia Pty Ltd
Fresenius Medical Care B, LLC
Fresenius Medical Care Beteiligungsgesellschaft mbH
Fresenius Medical Care Canada, Inc.
Fresenius Medical Care de Mexico, S.A. de C.V.
Key people
Harry de Wit
Member of the Management Board, Chief Executive Officer for Asia-Pacific · since 2016
Helen Giza
Chief Financial Officer, Member of the Management Board · since 2019
Frank Maddux
Member of the Management Board, Global Chief Medical Officer · since 2020
Katarzyna Mazur-Hofsaess
Member of the Management Board, Chief Executive Officer for Europe, Middle East and Africa (EMEA) · since 2018
Olaf Schermeier
Member of the Management Board, Chief Executive Officer for Research and Development · since 2013
Kent Wanzek
Member of the Management Board of the Company and Chief Executive Officer for Global Manufacturing and Quality & Supply · since 2010
Dieter Schenk
Chairman of the Supervisory Board · since 2018
William P. Johnston
Independent Member of the Supervisory Board · since 2006
Gregor Zuend
Independent Member of the Supervisory Board · since 2018
IPO date
Oct 02, 1996
Employees
124,295
Domiciled in
DE
Incorporated in
DE
Headquarters & legal address
Else-Kröner-Str. 1
Bad Homburg vor der Höhe, HE 61352
DE
Bad Homburg vor der Höhe, HE 61352
DE
Previous name
Fresenius Medical Care AG & Co. KGaA
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||